^
BIOMARKER:

PIK3CA E545K

i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Entrez ID:
Related biomarkers:
PIK3CA E545K
HCC
alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
PIK3CA E545K
CRC
cetuximab
Resistant: C3 – Early Trials
PIK3CA E545K
NSCLC
osimertinib
Resistant: C3 – Early Trials
PIK3CA E545K
Ovarian Cancer
TAS-117
Sensitive: C3 – Early Trials
PIK3CA E545K
Breast Cancer
olaparib + durvalumab + AZD5363
Sensitive: C3 – Early Trials
PIK3CA E545K
Gastric Cancer
CYH33
Sensitive: C4 – Case Studies
PIK3CA E545K
Breast Cancer
CYH33
Sensitive: C4 – Case Studies
PIK3CA E545K
Ovarian Cancer
CYH33
Sensitive: C4 – Case Studies
PIK3CA E545K
Breast Cancer
GDC-0941
Sensitive: D – Preclinical
PIK3CA E545K
Breast Cancer
MK-2206
Sensitive: D – Preclinical
PIK3CA E545K
Breast Cancer
lapatinib
Sensitive: D – Preclinical
PIK3CA E545K
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: D – Preclinical
PIK3CA E545K
Breast Cancer
trastuzumab + lapatinib
Resistant: D – Preclinical
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
PIK3CA E545K
SCCHN
RTB101
Sensitive: D – Preclinical
PIK3CA E545K
SCCHN
BMS-722782
Resistant: D – Preclinical
PIK3CA E545K
SCCHN
trametinib
Resistant: D – Preclinical
PIK3CA E545K
SCCHN
GDC-0941
Resistant: D – Preclinical
PIK3CA E545K
SCCHN
rigosertib
Sensitive: D – Preclinical
PIK3CA E545K
SCCHN
GDC-0032
Sensitive: D – Preclinical
PIK3CA E545K
Melanoma
vemurafenib
Resistant: D – Preclinical